Five States Join FTC Suit Against Hims & Hers Over Privacy Practices

Five US states joined the FTC's lawsuit against Hims & Hers, alleging deceptive privacy practices, including sharing sensitive health data with Meta and Snap. The amended complaint also accuses the company of misleading billing and cancellation practices. Hims & Hers plans to defend itself, while the FTC claims the company charges users before provider consultations and complicates cancellations. The company recently cut its full-year profit forecast due to higher costs.

Original reporting
Published Nov 12, 2026, 6:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Five States Join FTC Suit Against Hims & Hers Over Privacy Practices — source image
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

Regulatory enforcement adds a new risk factor, likely prompting a sell‑off and increased volatility.

02

Market read

First‑report of a multi‑state FTC action against a listed telehealth firm, creating immediate negative sentiment and trading opportunity.

03

What to watch

Potential insurance recoveries or the impact of the weight‑loss drug pivot could offset some downside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

The FTC expanded its original complaint to include five additional states, alleging privacy violations and deceptive billing by Hims & Hers Health.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

FTC lawsuit alleges Hims & Hers shared health data and engaged in deceptive billing, a fresh enforcement action not previously reported.

Expected impact

likely pressure as investors price in legal exposure and possible penalties

Evidence & confidence

New FTC action is material for a consumer‑health company; market typically reacts negatively to privacy and billing lawsuits.

Market effects

Telehealth and digital health firms may face heightened scrutiny on data handling practices.

U.S. market may see broader sell‑off in consumer‑health stocks pending regulatory reviews.

The case underscores global privacy enforcement trends, potentially influencing overseas digital‑health operators.

Counterpoint

If the company can quickly settle or prove compliance, the stock may rebound on short‑covering.

Key entities

  • Hims & Hers Health Inc.

    Telehealth provider facing FTC lawsuit over privacy and billing practices.

  • Federal Trade Commission

    U.S. agency filing the lawsuit and adding state participants.

Related articles

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.

$LLYHigh

More Good News for Eli Lilly Sends the Stock Even Higher

Eli Lilly (NYSE:LLY) shares rose after positive phase 3 trial results for retatrutide in treating knee osteoarthritis pain and weight loss. The company also partnered with Hims & Hers to expand access to GLP-1 drugs. Additionally, Lilly reported that Foundayo reduced sleep apnea severity, with FDA submission planned. Q3 revenue grew 39% to $24.4B, and earnings per share increased 16% to $7.22. Jefferies raised its price target to $1,700.

$HIMSHigh

Which Dates Could Move Hims & Hers Stock Most?

Hims & Hers Health (HIMS) stock fell 30.0% in November 2026, underperforming the S&P 500. The company cut its 2026 adjusted EBITDA guidance to $267M, citing challenges in the U.K. and Germany. It faces a securities class action related to an FTC complaint. Key events include slower U.S. weight loss marketing and a push into international markets, with fiscal Q4 subscriber numbers being a focus.